Press Release
Walden Biosciences Fully Enrolls First Cohort in Phase 2 Basket Study of WAL0921 in Chronic Kidney Diseases
September 30, 2024
Walden Biosciences Announces Research Collaboration with World Renowned Genetic Epidemiologist to Advance Work on Causal Role of suPAR in Chronic Kidney Disease
May 13, 2024
Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases
April 15, 2024
Walden Biosciences Expands Research Collaboration with the University of Michigan
January 10, 2024
Walden Biosciences to Host Virtual Event on November 14, 2023 “Transforming the Treatment Landscape of Chronic Kidney Disease”
November 7, 2023
Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases
June 5, 2023
